Papillary thyroid cancer (PTC) is the most common malignancy of all thyroid cancers. LncRNA LINC00460 has been proved to play roles in the oncogenesis and progression of various tumors, including papillary thyroid cancer. However, the potential molecular mechanism of LINC00460 in PTC is poorly investigated. LINC00460 was upregulated in PTC tissues and cells. Raf1 was upregulated in PTC tissues, but miR-485-5p was down-regulated. High LINC00460 expression was associated with poor prognosis. LINC00460 knockdown suppressed proliferation, migration, invation and EMT of PTC cells. Bioinformatics prediction revealed that LINC00460 had binding sites with miR-485-5p, which was validated by luciferase reporter assay. In addition, miR-485-5p was confirmed to directly target Raf1 3′-UTR. Moreover, LINC00460 promoted PTC progression by sponging miR-485-5p to elevate the expression of Raf1. Knockdown of LINC00460 restrained tumor growth in vivo. LINC00460 induced proliferation, migration, invation and EMT of PTC cells by regulating the LINC00460/miR-485-5p/Raf1 axis, which indicated that LINC00460 may be a potential biomarker and therapeutic target for PTC.

中文翻译：

---

LncRNA LINC00460通过调节LINC00460 / miR-485-5p / Raf1轴促进甲状腺乳头状癌的进展

甲状腺乳头状癌（PTC）是所有甲状腺癌中最常见的恶性肿瘤。LncRNA LINC00460已被证明在包括乳头状甲状腺癌在内的各种肿瘤的发生和发展中发挥作用。但是，对LINC00460在PTC中的潜在分子机理的研究很少。LINC00460在PTC组织和细胞中上调。Raf1在PTC组织中上调，但miR-485-5p下调。LINC00460高表达与不良预后相关。LINC00460组合式抑制PTC细胞的增殖，迁移，侵袭和EMT。生物信息学预测表明，LINC00460具有与miR-485-5p的结合位点，这已通过萤光素酶报告基因检测法得到验证。另外，证实miR-485-5p直接靶向Raf1 3'-UTR。此外，LINC00460通过使miR-485-5p海绵化以提高Raf1的表达来促进PTC的进展。敲低LINC00460可抑制体内肿瘤的生长。LINC00460通过调节LINC00460 / miR-485-5p / Raf1轴诱导PTC细胞的增殖，迁移，侵袭和EMT，这表明LINC00460可能是PTC的潜在生物标志物和治疗靶标。